See more : Digital Garage, Inc. (DLGEF) Income Statement Analysis – Financial Results
Complete financial analysis of Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jiangsu Jibeier Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Canada Rare Earth Corp. (RAREF) Income Statement Analysis – Financial Results
- COSCO SHIPPING Energy Transportation Co., Ltd. (600026.SS) Income Statement Analysis – Financial Results
- Vallabh Steels Limited (VALLABHSQ.BO) Income Statement Analysis – Financial Results
- Cloetta AB (publ) (CLA-B.ST) Income Statement Analysis – Financial Results
- Sichuan Guoguang Agrochemical Co., Ltd. (002749.SZ) Income Statement Analysis – Financial Results
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jibeier.com.cn
About Jiangsu Jibeier Pharmaceutical Co., Ltd.
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research, development, production, and sale of chemical preparations, proprietary Chinese medicine preparations, and bulk medicines. The company's products cover various therapeutic areas, such as improving white blood cells, enhancing immunity, treating joint diseases, anti-hypertension, anti-eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach diseases, and other diseases. The company was founded in 2001 and is based in Zhenjiang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 860.93M | 654.73M | 509.69M | 565.97M | 542.52M | 484.96M | 452.33M | 444.42M |
| Cost of Revenue | 95.15M | 76.17M | 62.12M | 62.87M | 63.89M | 64.17M | 67.20M | 68.62M |
| Gross Profit | 765.78M | 578.56M | 447.57M | 503.11M | 478.63M | 420.79M | 385.12M | 375.81M |
| Gross Profit Ratio | 88.95% | 88.37% | 87.81% | 88.89% | 88.22% | 86.77% | 85.14% | 84.56% |
| Research & Development | 55.77M | 55.18M | 29.28M | 33.55M | 31.16M | 19.60M | 17.14M | 16.75M |
| General & Administrative | 16.07M | 14.48M | 10.35M | 10.79M | 8.87M | 7.67M | 7.54M | 5.81M |
| Selling & Marketing | 401.87M | 310.91M | 260.16M | 287.65M | 275.05M | 249.04M | 232.10M | 230.29M |
| SG&A | 417.94M | 325.40M | 270.52M | 298.43M | 283.92M | 256.72M | 239.63M | 236.11M |
| Other Expenses | 42.95M | 38.18M | 37.45M | 36.87M | 33.20M | -976.48K | -607.06K | 8.64M |
| Operating Expenses | 516.66M | 418.76M | 337.25M | 368.85M | 348.28M | 309.30M | 292.04M | 291.59M |
| Cost & Expenses | 611.82M | 494.93M | 399.37M | 431.72M | 412.17M | 373.47M | 359.24M | 360.21M |
| Interest Income | 12.02M | 12.09M | 4.38M | 1.63M | 548.31K | 727.02K | 732.84K | 787.63K |
| Interest Expense | 243.44K | 376.23K | 105.62K | 114.84K | 126.45K | 100.63K | 350.72K | 1.79M |
| Depreciation & Amortization | 12.28M | 13.84M | 14.07M | 14.12M | 13.22M | 4.43M | 5.09M | 4.31M |
| EBITDA | 265.55M | 164.60M | 119.30M | 150.64M | 143.00M | 117.77M | 97.96M | 97.23M |
| EBITDA Ratio | 30.84% | 28.77% | 23.85% | 26.62% | 26.64% | 25.70% | 23.54% | 23.74% |
| Operating Income | 249.11M | 176.40M | 133.63M | 150.56M | 130.06M | 114.22M | 93.04M | 82.45M |
| Operating Income Ratio | 28.94% | 26.94% | 26.22% | 26.60% | 23.97% | 23.55% | 20.57% | 18.55% |
| Total Other Income/Expenses | -1.64M | -1.87M | -1.07M | -2.03M | -271.63K | -976.48K | -607.06K | 8.64M |
| Income Before Tax | 247.48M | 174.53M | 132.56M | 148.53M | 129.78M | 113.24M | 92.44M | 91.09M |
| Income Before Tax Ratio | 28.75% | 26.66% | 26.01% | 26.24% | 23.92% | 23.35% | 20.44% | 20.50% |
| Income Tax Expense | 28.71M | 20.27M | 18.22M | 18.67M | 17.00M | 16.33M | 14.83M | 13.24M |
| Net Income | 219.09M | 154.67M | 114.90M | 129.72M | 112.91M | 96.61M | 77.52M | 76.94M |
| Net Income Ratio | 25.45% | 23.62% | 22.54% | 22.92% | 20.81% | 19.92% | 17.14% | 17.31% |
| EPS | 1.17 | 0.83 | 0.61 | 0.69 | 0.60 | 0.69 | 0.55 | 0.55 |
| EPS Diluted | 1.17 | 0.83 | 0.61 | 0.69 | 0.60 | 0.69 | 0.55 | 0.55 |
| Weighted Avg Shares Out | 187.25M | 186.94M | 186.94M | 186.94M | 186.94M | 140.02M | 140.95M | 139.89M |
| Weighted Avg Shares Out (Dil) | 187.25M | 186.94M | 186.94M | 186.94M | 186.94M | 140.02M | 140.95M | 139.89M |
Source: https://incomestatements.info
Category: Stock Reports